Similarly, a higher risk of 1p19q LOH was observed in CIMP + glioma (OR 5.65; 95% CI 2.66–12.01; P = .01, Pheterogeneity 0.040), whereas EGFR mutation and MGMT promoter methylation did not show any differences between the 2 types of gliomas [(OR 0.14; 95% CI 0.05–0.43; P = .35; Pheterogeneity 0.002) and (OR 3.01; 95% CI 0.79–11.48; P = .10; Pheterogeneity 0.825)] (Fig. 3). The gene discussed is EGFR; the disease is central nervous system cancer.